Skip to main content

Table 1 Demographic and surgical characteristics at baseline

From: Higher incidence of acute respiratory distress syndrome in cardiac surgical patients with elevated serum procalcitonin concentration: a prospective cohort study

 PCT elevated
(n = 64)
Control
(n = 232)
p value
Age (years, old)61.0 ± 9.960.8 ± 10.30.904
Male, n (%)41 (64.1)119 (51.3)0.070
Smoker, n (%)14 (21.9)52 (22.4)0.927
Coexisting conditions   
 Hypertension, n (%)30 (46.9)117 (50.4)0.614
 Diabetes mellitus, n (%)18 (28.1)65 (28)0.986
 Coronary artery disease, n (%)52 (81.3)176 (75.9)0.364
 NYHA grade III–IV, n (%)34 (53.1)132 (56.9)0.590
 Liver disease, n (%)3 (4.7)5 (2.2)0.269
Preoperative drug therapy   
 ACEI, n (%)16 (25)46 (19.8)0.368
 Beta-blocker, n (%)21 (32.8)71 (30.6)0.735
 Calcium channel blocker, n (%)18 (28.1)59 (25.4)0.664
 Aspirin, n (%)32 (50)99 (42.7)0.296
 Aspirin + clopidogrel, n (%)20 (31.3)56 (24.1)0.249
Preoperative troponin I (ng/mL)0.07 ± 0.040.08 ± 0.060.336
Preoperative Nt-pro-BNP (pg/mL)826 ± 301772 ± 2940.201
Surgery type  0.080
 CABG, n (%)52 (81.3)155 (66.8)0.078
 Valve replacement, n (%)9 (14.1)61 (26.3)0.123
 Other, n (%)a3 (4.7)16 (6.9)> 0.999
Operation duration (min)305.7 ± 63.5264.4 ± 51.1< 0.001*
CPB time (min)147.2 ± 32135.6 ± 22.30.008*
Aortic clamping time (min)84.5 ± 17.678.4 ± 18.20.017*
Intraoperative fluid balance (mL)124 ± 203109 ± 2290.626
RBC infusion (mL)259 ± 316183 ± 2150.530
FFP infusion (mL)294 ± 325215 ± 2280.306
  1. PCT procalcitonin, NYHA New York Heart Association, ACEI angiotensin converting enzyme inhibitor, Nt-pro-BNP N-terminal pro-B-type natriuretic peptide, CABG coronary artery bypass grafting, CPB cardiopulmonary bypass, RBC red blood cell, FFP fresh frozen plasma
  2. p < 0.05
  3. aIncluding adult congenital heart procedure, great artery surgery and combined surgery